RYDAPT, generically known as midostaurin, is a targeted therapy medication used in the treatment of certain types of blood cancers. Specifically, it is approved for use in adults with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive, as detected by an FDA-approved test, in combination with standard chemotherapy. RYDAPT is also indicated for the treatment of adults with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL). It works by inhibiting multiple enzymes that promote cell growth, thereby blocking the proliferation of cancerous cells. Administered orally, RYDAPT is a part of a class of drugs known as kinase inhibitors and represents a significant advancement in targeted cancer therapy, offering hope for improved outcomes in patients with these challenging conditions.